Didem Didar Balci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Didem Didar Balci has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Melis Gönülal
Department of Dermatology, Izmir City Hospital, İzmir, Turkey
4 shared publications Esin Atik
3 shared publicationsCigdem Asena Dogramaci
Mustafa Kemal University, Faculty of Medicine, Department of Dermatology, Antakya, Turkey
2 shared publicationsEbru Celik
2 shared publicationsJülide Zehra Yenin
2 shared publicationsNizami Duran
2 shared publications
Latest Publications
- 1 April 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (8) , 692-697
Toxic Epidermal Necrolysis Mimicking Linear IgA Bullous Dermatosis Without Mucosal Involvement: A Rare Case Report
Toxic epidermal necrolysis (TEN) is defined histopathologically by full‐thickness epidermal necrosis with sparse dermal inflammation. Because mucosal involvement is considered a hallmark feature, mucosal‐sparing TEN is exceedingly rare and may mimic other subepidermal blistering disorders. We report an amoxicillin/clavulanate–induced TEN case presenting with tense annular vesiculobullous lesions with a “string‐of‐pearls” appearance clinically suggestive of linear IgA bullous dermatosis (LABD). However, histopathology showed widespread keratinocyte necrosis across all epidermal layers and minimal perivascular lymphocytic infiltration, without neutrophilic microabscesses. Two perilesional direct immunofluorescence (DIF) studies were negative for linear IgA deposition, effectively excluding LABD. This case underscores the diagnostic importance of early histopathologic and DIF evaluation of TEN cases with atypical mucosal‐sparing presentations that clinically overlap with autoimmune blistering diseases.
- 1 April 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (8) , 692-697
Toxic Epidermal Necrolysis Mimicking Linear IgA Bullous Dermatosis Without Mucosal Involvement: A Rare Case Report
Toxic epidermal necrolysis (TEN) is defined histopathologically by full‐thickness epidermal necrosis with sparse dermal inflammation. Because mucosal involvement is considered a hallmark feature, mucosal‐sparing TEN is exceedingly rare and may mimic other subepidermal blistering disorders. We report an amoxicillin/clavulanate–induced TEN case presenting with tense annular vesiculobullous lesions with a “string‐of‐pearls” appearance clinically suggestive of linear IgA bullous dermatosis (LABD). However, histopathology showed widespread keratinocyte necrosis across all epidermal layers and minimal perivascular lymphocytic infiltration, without neutrophilic microabscesses. Two perilesional direct immunofluorescence (DIF) studies were negative for linear IgA deposition, effectively excluding LABD. This case underscores the diagnostic importance of early histopathologic and DIF evaluation of TEN cases with atypical mucosal‐sparing presentations that clinically overlap with autoimmune blistering diseases.
- Open Access
- 2 August 2023
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 34 (1) , 2241941
Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience
This work aimed to investigate the long-term clinical experience with ustekinumab in cases with psoriasis. This retrospective cohort research group consisted of cases who presented to the dermatology outpatient clinics between January 2015 and January 2021, diagnosed with psoriasis, and were treated with ustekinumab. Data including gender, age, weight, disease duration, naïve and non-naïve status, psoriasis type, duration of medication, comorbidities, psoriasis area and severity index scores, the causes of treatment discontinuation, and previous treatments were retrospectively reviewed and analyzed. 160 cases with psoriasis were treated with ustekinumab during the research period. Twenty-four patients were excluded. Among 136 cases, 84 (61.8%) were male and 52 (38.2%) were female. We determined 80.55% of the non-naïve cases responded to ustekinumab. Ustekinumab can be a suitable treatment option for non-naïve and resistant patients. Our data suggest the positive effect persists in cases with favorable responses to the first or second dose of ustekinumab. Also, we determined male cases gave more rapid and more robust responses than female cases, and patients were more willing about continuing the treatment.
- 2 August 2023
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 34 (1) , 2241941
Open AccessEffectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience
This work aimed to investigate the long-term clinical experience with ustekinumab in cases with psoriasis. This retrospective cohort research group consisted of cases who presented to the dermatology outpatient clinics between January 2015 and January 2021, diagnosed with psoriasis, and were treated with ustekinumab. Data including gender, age, weight, disease duration, naïve and non-naïve status, psoriasis type, duration of medication, comorbidities, psoriasis area and severity index scores, the causes of treatment discontinuation, and previous treatments were retrospectively reviewed and analyzed. 160 cases with psoriasis were treated with ustekinumab during the research period. Twenty-four patients were excluded. Among 136 cases, 84 (61.8%) were male and 52 (38.2%) were female. We determined 80.55% of the non-naïve cases responded to ustekinumab. Ustekinumab can be a suitable treatment option for non-naïve and resistant patients. Our data suggest the positive effect persists in cases with favorable responses to the first or second dose of ustekinumab. Also, we determined male cases gave more rapid and more robust responses than female cases, and patients were more willing about continuing the treatment.
- Open Access
- 31 October 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (12) , e15955
Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real‐world experience
Real‐life data about any particular treatment is very helpful for clinicians, particularly when managing a chronic disease such as psoriasis. In our study, we aimed to reflect our clinical experience during 48 weeks with an IL‐17 antagonist ixekizumab. This study was designed as a retrospective multi‐center study. Four tertiary referral centers participated into the study. The patients who did not present to the clinics for 3rd month follow‐up were excluded. Data including gender, age, weight, type of psoriasis, additional sites on the body, disease duration, previous treatments, duration of medication of ixekizumab, psoriasis area and severity index scores, previous treatments, and comorbidities, the reasons for drug discontinuation, adverse effects and the patients' naïve or non‐naïve status were retrieved from electronic patient folders. Although 267 patients met the inclusion criteria, 28 patients were excluded since they did not present to the clinic for 3rd month follow‐up so 239 cases were included mmüne research. We determined significant correlations between naive and non‐naive cases about getting PASI 75 and PASI 90 responses for all cases ( p = 0.005 and p = 0.028, respectively) and between comorbid and non‐comorbid cases about getting PASI 90 and PASI 100 responses for all cases ( p = 0.021 and p = 0.029, respectively). When we investigate as female and male patients separately, non‐comorbid female cases can achieve PASI 100 response significantly easier than comorbid female patients ( p = 0.019). Clinicians can use ixekizumab safely mmüne treatment of their patients with psoriasis and get PASI 75‐90‐100 responses quickly. Ixekizumab is more effective for naive cases but it may also be a treatment option for biologic experienced patients. The ratio of PASI 75‐90‐100 responses are better in non‐comorbid cases than comorbid patients nevertheless ixekizumab is a quite effective agent mmüne treatment of comorbid cases.
- 31 October 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (12) , e15955
Open AccessIxekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real‐world experience
Real‐life data about any particular treatment is very helpful for clinicians, particularly when managing a chronic disease such as psoriasis. In our study, we aimed to reflect our clinical experience during 48 weeks with an IL‐17 antagonist ixekizumab. This study was designed as a retrospective multi‐center study. Four tertiary referral centers participated into the study. The patients who did not present to the clinics for 3rd month follow‐up were excluded. Data including gender, age, weight, type of psoriasis, additional sites on the body, disease duration, previous treatments, duration of medication of ixekizumab, psoriasis area and severity index scores, previous treatments, and comorbidities, the reasons for drug discontinuation, adverse effects and the patients' naïve or non‐naïve status were retrieved from electronic patient folders. Although 267 patients met the inclusion criteria, 28 patients were excluded since they did not present to the clinic for 3rd month follow‐up so 239 cases were included mmüne research. We determined significant correlations between naive and non‐naive cases about getting PASI 75 and PASI 90 responses for all cases ( p = 0.005 and p = 0.028, respectively) and between comorbid and non‐comorbid cases about getting PASI 90 and PASI 100 responses for all cases ( p = 0.021 and p = 0.029, respectively). When we investigate as female and male patients separately, non‐comorbid female cases can achieve PASI 100 response significantly easier than comorbid female patients ( p = 0.019). Clinicians can use ixekizumab safely mmüne treatment of their patients with psoriasis and get PASI 75‐90‐100 responses quickly. Ixekizumab is more effective for naive cases but it may also be a treatment option for biologic experienced patients. The ratio of PASI 75‐90‐100 responses are better in non‐comorbid cases than comorbid patients nevertheless ixekizumab is a quite effective agent mmüne treatment of comorbid cases.
- Open Access
- 1 September 2021
- Published by Galenos Yayinevi in Journal of the Turkish Academy of Dermatology
- Vol. 15 (3) , 76-79
Treatment of Two Patients with Erythrodermic Psoriasis with Ixekizumab During COVID-19 Pandemic
- 1 September 2021
- Published by Galenos Yayinevi in Journal of the Turkish Academy of Dermatology
- Vol. 15 (3) , 76-79
Open AccessTreatment of Two Patients with Erythrodermic Psoriasis with Ixekizumab During COVID-19 Pandemic
- 11 June 2021
- Published by Galenos Yayinevi in Journal of the Turkish Academy of Dermatology
- Vol. 15 (2) , 49-52
Rituximab and IVIG for the Treatment of Bullous Pemphigoid: Critical Analysis of the Current Literature
- 11 June 2021
- Published by Galenos Yayinevi in Journal of the Turkish Academy of Dermatology
- Vol. 15 (2) , 49-52
Rituximab and IVIG for the Treatment of Bullous Pemphigoid: Critical Analysis of the Current Literature
- 5 March 2021
- Published by Galenos Yayinevi in Journal of the Turkish Academy of Dermatology
- Vol. 15 (1) , 27-29
Two Patients with Psoriasis and Hepatitis B Treated with Secukinumab During COVID-19 Pandemic
- 5 March 2021
- Published by Galenos Yayinevi in Journal of the Turkish Academy of Dermatology
- Vol. 15 (1) , 27-29
Two Patients with Psoriasis and Hepatitis B Treated with Secukinumab During COVID-19 Pandemic
- Open Access
- 1 January 2020
- Published by XMLink in Annals of Dermatology
- Vol. 32 (3) , 181-188
Internalized Stigma in Pediatric Psoriasis: A Comparative Multicenter Study
Alpsoy E, et al. Ann Dermatol. 2020 Jun;32(3):181-188. https://doi.org/10.5021/ad.2020.32.3.181
- 1 January 2020
- Published by XMLink in Annals of Dermatology
- Vol. 32 (3) , 181-188
Open AccessInternalized Stigma in Pediatric Psoriasis: A Comparative Multicenter Study
Alpsoy E, et al. Ann Dermatol. 2020 Jun;32(3):181-188. https://doi.org/10.5021/ad.2020.32.3.181
- 2 May 2012
- Vol. 10 (2) , 112-3
Inflammatory linear verrucous epidermal nevus with genital involvement.
An 18-year-old woman was admitted to our clinic complaining of pruritic lesions on her inguinal and genital areas that had been present since birth. She had previously used topical steroids and a combination of topical steroids and calcipotriol for approximately 6 months; however, the treatment was unsuccessful. Her medical history was unremarkable. On dermatologic examination, mild erythematous, lichenified, and verrucous papules occurring in a linear pattern on the right inguinal area and on the region extending from the right labium majus to the perianal area were noted (Figure). Additionally, an erythematous area with central erosion surrounded by maceration was noted on the intergluteal area. Two separate punch biopsy samples were obtained from the erythematous, lichenified, verrucous, papular lesion on the inguinal area and from the erythematous, eroded, macerated lesion on the intergluteal area. Histopathological examination of both biopsy specimens revealed a thin orthokeratotic layer and scattered parakeratotic layers, as well as papillomatosis and acanthosis of the epidermis with a slight hyperpigmentation of the basal layer. A mild, perivascular, chronic inflammatory cell infiltration was noted in the dermis. Based on the clinical and histopathological findings, the patient was considered to have inflammatory linear verrucous epidermal nevus, and cryotherapy was initiated. At the 2-week follow-up after the first application, it was observed that the itching complaint decreased substantially and the eroded lesions in the intergluteal area were re-epithelialized. On clinical follow-up, no improvement was observed in the papular component of the lesion after 4 sessions of cryotherapy. The patient voluntarily discontinued the follow-up after 4 sessions of cryotherapy.
- 2 May 2012
- Vol. 10 (2) , 112-3
Inflammatory linear verrucous epidermal nevus with genital involvement.
An 18-year-old woman was admitted to our clinic complaining of pruritic lesions on her inguinal and genital areas that had been present since birth. She had previously used topical steroids and a combination of topical steroids and calcipotriol for approximately 6 months; however, the treatment was unsuccessful. Her medical history was unremarkable. On dermatologic examination, mild erythematous, lichenified, and verrucous papules occurring in a linear pattern on the right inguinal area and on the region extending from the right labium majus to the perianal area were noted (Figure). Additionally, an erythematous area with central erosion surrounded by maceration was noted on the intergluteal area. Two separate punch biopsy samples were obtained from the erythematous, lichenified, verrucous, papular lesion on the inguinal area and from the erythematous, eroded, macerated lesion on the intergluteal area. Histopathological examination of both biopsy specimens revealed a thin orthokeratotic layer and scattered parakeratotic layers, as well as papillomatosis and acanthosis of the epidermis with a slight hyperpigmentation of the basal layer. A mild, perivascular, chronic inflammatory cell infiltration was noted in the dermis. Based on the clinical and histopathological findings, the patient was considered to have inflammatory linear verrucous epidermal nevus, and cryotherapy was initiated. At the 2-week follow-up after the first application, it was observed that the itching complaint decreased substantially and the eroded lesions in the intergluteal area were re-epithelialized. On clinical follow-up, no improvement was observed in the papular component of the lesion after 4 sessions of cryotherapy. The patient voluntarily discontinued the follow-up after 4 sessions of cryotherapy.
- Open Access
- 1 January 2011
- Published by XMLink in Annals of Dermatology
- Vol. 23 (Suppl 3) , S375-S379
The Co-Existence of Vulvar Lichen Sclerosus, Ulcerated Calcinosis Cutis, and Dermatomyositis: Coincidence or Immunological Mechanism?
Balcı DD, et al. Ann Dermatol. 2011 Dec;23(Suppl 3):S375-S379. http://dx.doi.org/10.5021/ad.2011.23.S3.S375
- 1 January 2011
- Published by XMLink in Annals of Dermatology
- Vol. 23 (Suppl 3) , S375-S379
Open AccessThe Co-Existence of Vulvar Lichen Sclerosus, Ulcerated Calcinosis Cutis, and Dermatomyositis: Coincidence or Immunological Mechanism?
Balcı DD, et al. Ann Dermatol. 2011 Dec;23(Suppl 3):S375-S379. http://dx.doi.org/10.5021/ad.2011.23.S3.S375
- 24 July 2009
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 7 (8) , 688-691
DLQI scores in patients with keloids and hypertrophic scars: a prospective case control study
Summary: Background: Keloids and hypertrophic scars (HTS) can cause functional impairment and psychosocial burdens, both of which affects quality of life (QoL). Our aim was to compare Dermatology Life Quality Index (DLQI) scores in patients with keloids and HTS to those of psoriasis patients and normal controls. Patients and Methods: Forty‐eight consecutive patients with keloids and HTS and 48 with psoriasis vulgaris attending our dermatology outpatient clinic, as well as 48 sex‐ and age‐matched healthy controls completed the DLQI. Results: Total DLQI scores of patients with keloids and HTS (7.79 ± 5.10) and psoriasis (8.73 ± 5.63) were comparable and significantly higher than that of healthy controls (0.58 ± 0.77). No significant difference were found between patients with psoriasis and patients with keloids and HTS in terms of the total DLQI scores and the subscale scores (p > 0.05) except “treatment” (p < 0.05) sub‐scale scores which were higher in psoriasis. Conclusions: The QoL of patients with keloids and HTS is impaired as much as that of those with psoriasis. The DLQI questionnaire is a reliable and valid instrument for assessing the QoL in patients with keloids and HTS.
- 24 July 2009
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 7 (8) , 688-691
DLQI scores in patients with keloids and hypertrophic scars: a prospective case control study
Summary: Background: Keloids and hypertrophic scars (HTS) can cause functional impairment and psychosocial burdens, both of which affects quality of life (QoL). Our aim was to compare Dermatology Life Quality Index (DLQI) scores in patients with keloids and HTS to those of psoriasis patients and normal controls. Patients and Methods: Forty‐eight consecutive patients with keloids and HTS and 48 with psoriasis vulgaris attending our dermatology outpatient clinic, as well as 48 sex‐ and age‐matched healthy controls completed the DLQI. Results: Total DLQI scores of patients with keloids and HTS (7.79 ± 5.10) and psoriasis (8.73 ± 5.63) were comparable and significantly higher than that of healthy controls (0.58 ± 0.77). No significant difference were found between patients with psoriasis and patients with keloids and HTS in terms of the total DLQI scores and the subscale scores (p > 0.05) except “treatment” (p < 0.05) sub‐scale scores which were higher in psoriasis. Conclusions: The QoL of patients with keloids and HTS is impaired as much as that of those with psoriasis. The DLQI questionnaire is a reliable and valid instrument for assessing the QoL in patients with keloids and HTS.